Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Considers Sale, Spin-Off For Ortho-Clinical Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson announced plans to evaluate strategic options for its Ortho-Clinical Diagnostics unit during the firm’s medical devices and diagnostics business review.

You may also be interested in...



Device/Diagnostics Quarterly Deal Statistics, Q1 2014

Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.

News Briefs: Medtronic’s CoreValve Approval; J&J Dx Unit Set For Sale; Google’s Glucometer Contact Lens

Medtronic gains FDA approval for its transcather CoreValve system months earlier than predicted. The Carlyle Group makes binding offer for J&J’s Ortho-Clinical Diagnostics business. Google is developing a wireless glucometer embedded within a contact lens. More news briefs.

Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J And Novartis (Part 3)

In Part 3 of our feature, we take a closer look at the first quarterly calls for Abbott and AbbVie after the company split in two, plus the latest on emerging markets from J&J and Novartis.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT032461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel